PCI Biotech Holding ASA (OSL:PCIB) EPS without NRI: kr-0.55 (TTM As of Jun. 2025)


OSL:PCIB PCI Biotech Holding ASA OSL:PCIB
6 GF Score
Price kr0.12
! 1 Warning Sign
View Full Analysis

What is PCI Biotech Holding ASA EPS without NRI?

PCI Biotech Holding ASA OSL:PCIB -12.21% 6 EPS without NRI is kr-0.55 as of Jun. 2025. GuruFocus rates OSL:PCIB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

PCI Biotech Holding ASA's earnings per share without non-recurring items for the six months ended in Jun. 2025 was kr-0.31. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2025 was kr-0.55.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 43.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 30.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for PCI Biotech Holding ASA's EPS without NRI or its related term are showing as below:

OSL:PCIB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.5   Med: -0.25   Max: 43
Current: 43

During the past 13 years, PCI Biotech Holding ASA's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 43.00% per year. The lowest was -44.50% per year. And the median was -0.25% per year.

OSL:PCIB's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 16.75 vs OSL:PCIB: 43.00

PCI Biotech Holding ASA's EPS (Diluted) for the six months ended in Jun. 2025 was kr-0.31. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was kr-0.55.

PCI Biotech Holding ASA's EPS (Basic) for the six months ended in Jun. 2025 was kr-0.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2025 was kr-0.55.


PCI Biotech Holding ASA  (OSL:PCIB) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


PCI Biotech Holding ASA EPS without NRI Related Terms


PCI Biotech Holding ASA EPS without NRI Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA EPS without NRI Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.94 -2.37 -1.48 -0.54 -0.44

PCI Biotech Holding ASA Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.32 -0.23 -0.20 -0.24 -0.31

OSL:PCIB vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, PCI Biotech Holding ASA's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's PE Ratio without NRI falls into.


OSL:PCIB
6GF Score
PCI Biotech Holding ASA OSL:PCIB
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PCI Biotech Holding ASA EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of kr-0.55 mean?
PCI Biotech Holding ASA (OSL:PCIB) has a EPS without NRI of kr-0.55 as of Jun. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's EPS without NRI too high?
PCI Biotech Holding ASA's current EPS without NRI is kr-0.55. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does PCI Biotech Holding ASA's EPS without NRI compare to VRTX and REGN?
PCI Biotech Holding ASA's EPS without NRI of kr-0.55 can be compared against companies in the Biotechnology industry. The industry median EPS without NRI is 16.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.75, based on 1,170 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on PCI Biotech Holding ASA and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PCI Biotech Holding ASA's current EPS without NRI is kr-0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (OSL:PCIB) has a current EPS without NRI of kr-0.55. The current EPS without NRI is kr-0.55. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current EPS without NRI is kr-0.55 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Address Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
6GF Score

Get the complete analysis for OSL:PCIB

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12
Price